SCHEMBL16748438

SCHEMBL16748438

Cc1nc2ccccc2n1-c1nc(N)nc(Nc2ccc(N3CCOCC3)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.61
PIK3CA P42336 4/20 0.61
PIK3CB P42338 4/20 0.61
PIK3CG P48736 4/20 0.61
KDR P35968 1/20 0.54
PTK2 Q05397 1/20 0.54
MAPK1 P28482 2/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.53
IGF1R P08069 1/20 0.51
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 2/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740776 0.84 BMI1 (0.59) PIK3CDPIK3CAPIK3CBPIK3CGKDR
SCHEMBL16740749 0.82 TUBB4A (0.56) PIK3CDPIK3CAPIK3CBPIK3CGEGFR
SCHEMBL16740753 0.82 PIK3CD (0.53) PIK3CDPIK3CAPIK3CBPIK3CGKDR
SCHEMBL16740762 0.81 PIK3CD (0.51) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16740712 0.81 BMI1 (0.62) PIK3CDPIK3CAPIK3CBPIK3CGKDR
SCHEMBL16748479 0.80 BMI1 (0.62) PIK3CDPIK3CAPIK3CBPIK3CGMAPK1
SCHEMBL16740792 0.80 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL16740834 0.78 MEN1 (0.47) PIK3CDPIK3CAPIK3CBPIK3CGMAPK1
SCHEMBL16748475 0.77 CHRNA7 (0.51) PIK3CDPIK3CAPIK3CBPIK3CGMAPT
SCHEMBL16748480 0.77 BMI1 (0.64) PIK3CDPIK3CAPIK3CBPIK3CGMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B PIK3CD 2974/4885PIK3CA 3534/4885PIK3CB 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.